Search PubMedSearch

Biomedical subjects

J W Berman

Publications and source records attributed to J W Berman.

At least 19 recordsLinked to original sources

The role of the blood-brain barrier in HIV infection of the central nervous system.

The blood-brain barrier (BBB) functions to regulate the entry of macromolecules, microbial pathogens, and circulating leukocytes into the central nervous system (CNS). It consists, in part, of the microvascular endothelium and associated astrocyte foot processes, found in close apposition to the abluminal side of the vascular endothelial cells (EC). During the pathogenesis of certain nervous system diseases with inflammatory components, the BBB may function to facilitate the entry of leukocytes into the CNS parenchyma. A common histologic observation in human immunodeficiency virus type-1 (HIV) encephalitis is the localization of HIV proteins to multinucleated giant cells that co-immunolabel with antibodies specific for cells of the monocyte/macrophage lineage, suggesting that HIV can enter the CNS as cell-associated virus. We previously characterized a tissue culture model of the BBB that consists of the co-culture of autologous EC and astrocytes. In this presentation, we used this model to examine the expression of adhesion molecules by both the EC and astrocyte components of this BBB model, and to characterize the interactions between HIV-infected monocytes and EC. The data presented in this review of our work demonstrates that astrocytes upregulate the expression of intercellular adhesion molecule (ICAM-1) by EC. In a parallel study, western blot analysis demonstrated that ICAM-1 is also expressed in the developing human CNS. When exposed to the proinflammatory cytokine tumor necrosis factor alpha (TNF), both EC cocultured with astrocytes and astrocytes cultured alone expressed the adhesion proteins IG9, ICAM-1, vascular cell adhesion molecule 1 (VCAM) and E-selection.(ABSTRACT TRUNCATED AT 250 WORDS)

Astrocytes

Tumor necrosis factor alpha induces adhesion molecule expression on human fetal astrocytes.

Leukocyte adhesion molecules on endothelial cells of the blood-brain barrier may participate in the entry of leukocytes into the central nervous system. Because astrocytes are also a component of the blood-brain barrier and have been associated with inflammation, we studied the ability of astrocytes to express leukocyte adhesion molecules using Northern blot and immunocytochemical techniques. Astrocytes treated with the proinflammatory cytokine tumor necrosis factor alpha (TNF) expressed messenger RNA for the adhesion molecules E-selectin, vascular cell adhesion molecule 1, and intercellular adhesion molecule 1, as well as their corresponding proteins. In addition, TNF-treated astrocytes expressed a monocyte adhesion protein identified by our laboratory, recognized by the monoclonal antibody IG9. These results indicate that under inflammatory conditions in the central nervous system, such as multiple sclerosis and acquired immune deficiency syndrome, astrocyte expression of adhesion molecules may facilitate the migration of leukocytes and contribute to the disease process.

Astrocytes

Interleukin 6 modulates c-sis gene expression in cultured human endothelial cells.

Human vascular endothelial cells secrete platelet-derived growth factor (PDGF)-like polypeptides which may mediate some of the vascular effects in the inflammatory process. We have demonstrated that IL-6 caused a significant increase in the mRNA level of the c-sis gene (PDGF B chain) in cultured human endothelial cells. IL-1 alpha and IL-1 beta also increased c-sis mRNA transcripts after an extended incubation period and both cytokines acted synergistically with IL-6 in increasing c-sis expression. Tumor necrosis factor enhanced the accumulation of c-sis mRNA and interferon-gamma decreased its level. In the inflammatory process specific cytokines can modulate c-sis expression in human endothelial cells. Their subsequent production of PDGF-like polypeptides could stimulate cell migration and proliferation, and cause the release of vascular inflammatory mediators.

Cells, Cultured

Chronic inflammatory effects of interleukin-1 on the blood-retina barrier.

The chronic effects of human recombinant IL-1 (hrIL-1) on the specialized vasculature of the central nervous system (CNS) and on the CNS itself have been examined over a 35-day period in the rabbit retina. A single intraocular injection of physiological levels of hrIL-1 (300 units) induced a biphasic inflammatory reaction with well-defined acute and chronic phases in the challenged eye. Quantitative histopathological examination of the vascularized portion of the retina in the IL-1-challenged eye documented a persistent mononuclear (MN) cell response that peaked 7-14 days post-challenge. Included in the MN cell count were perivascular plasma cells. Elevated protein levels in the vitreous persisted throughout the time points studied and alterations in vascular permeability of the epiretinal vessels were demonstrated by tracer leakage at 2 weeks post-challenge. The results show that exposure of the CNS-vasculature to IL-1 induces long-lasting inflammatory changes typical of a chronic inflammatory reaction.

Animals

Pathophysiologic effect of interleukin-1b in the rabbit retina.

Interleukin-1 is a potent immunomodulator and has been shown to initiate many aspects of the inflammatory response. To determine the effects of IL-1b in the central nervous system (CNS), the rabbit retina was used, adjacent to which factors can be injected with minimal trauma and both pathologic and physiologic effects can be monitored. Intravitreal injection of 300 units of IL-1b induced an alteration in the visual evoked potentials (VEP) that was associated with marked intravascular red blood cell accumulations, hemorrhage, and cellular inflammation of the epiretinal vessels. Analysis of these events showed slowing and occasional hyper-excitability of the compound action potential of the optic tract and of the cortical VEP that correlate with the maximum inflammatory response. Histologic studies show the following: no apparent response occurs within the first 1.5 hours after intraocular challenge; and between 3 and 6 hours after injection an extensive intravascular red blood cell accumulation and progressive hemorrhage is accompanied by an increase in the number of mononuclear (MN) cells and the appearance of polymorphonuclear (PMN) cells. Polymorphonuclear cells continue to increase with time to give a single wave of inflammation that peaks 24 hours after injection, while the number of MN cells steadily increases. These events are associated with changes in the permeability of the blood-brain barrier and correlate with the electrophysiologic dysfunctions. Forty-one hours after injection, MN inflammation, reactive gliosis, and residual PMN inflammation are evident. Neutralization with specific antibody inhibited the responses through 6 hours after injection. It is concluded that the rabbit retina provides a valuable model for the in vivo analysis of CNS inflammation.

Animals

Differences in activities of murine retroviral long terminal repeats in cytotoxic T lymphocytes and T-lymphoma cells.

Transcriptional activities of the long terminal repeats (LTRs) of various murine leukemia viruses were tested in the cytotoxic T-cell lines CTLL-1 and CTLL-2. In contrast to T-lymphoma cells, in which the LTRs of T-lymphomagenic virus SL3-3 and Moloney murine leukemia virus are more active than those of other viruses, transcriptional activity in these mature, interleukin-2-dependent cells is not correlated with the specificity of viral leukemogenicity. Several approaches were used to investigate the molecular basis for LTR activity differences in lymphoma cells and mature cytotoxic T cells. Deletion analysis of the Moloney virus LTR showed that the direct repeats associated with enhancer activity have, at most, a slight effect on expression in CTLL-1 cells, whereas they stimulate expression six- to eightfold in T-lymphoma cells. This suggests that the mature T-cell line lacks one or more factors present in T-lymphoma cells that function to augment transcription from the Moloney murine leukemia virus LTR. We also used recombinant viral LTRs to investigate the role of the enhancer core element of SL3-3 in CTLL-1 and CTLL-2 cells. A one-base-pair difference between the core sequences of SL3-3 and nonleukemogenic Akv virus, which is important for SL3-3 activity in T-lymphoma cells, had no effect in these cells. The inability to distinguish the single-base-pair difference in expression assays was correlated with the absence of binding of a cellular factor, S-CBF, to the SL3-3 enhancer core in extracts of CTLL-1 and CTLL-2 nuclei. These studies may have implications for identification of the target cells for viral leukemogenesis, as well as for tracing of changes in the transcriptional machinery during T-lymphocyte differentiation.

Cell Line

Differential expression of surface markers on thymic lymphomas induced by two carcinogenic agents in different mouse strains.

Expression of several thymocyte surface antigens was monitored in a murine model system of thymic lymphoma induction in two different strains of mice. RF/J mice are sensitive to tumor induction by N-nitrosomethylurea (NMU) and by gamma-irradiation, while 129/J mice form tumors only upon NMU treatment. Latency periods for tumor formation were characteristically different depending upon the inducing agent and the mouse strain. We observed differences in thymic leukemia antigen and H-2K expression according to the mode of tumor induction and in relation to the mouse strain, implying multiple factors involved in target cell selection and tumor progression.

Animals

Oncogene activation and surface markers in mouse lymphomas induced by radiation and nitrosomethylurea.

Thymic lymphomas have been induced by gamma-radiation and treatment with the chemical nitrosomethylurea in different mice strains. As indicated by the NIH 3T3 focus forming assay, a significant percentage of the tumors contain activated oncogenes of the ras family (K or N). Cloning and sequencing has enabled us to identify single base mutations as the only significant alteration present in the activated oncogenes. These alterations result in the substitution of amino-acid 12 or 61 of the p21 product of the ras genes. With the use of synthetic oligonucleotides it has been found that the tumors do not all contain the same mutation and in one case so far the normal allele is absent.

Animals

Thy-1 antigen expression by murine hematopoietic precursor cells.

Multipotential lymphohematopoietic stem cells detected by a 12-day spleen colony assay are uniformly Thy-1 positive. As these cells differentiate into stem cells with restricted developmental potential, the antigen is lost. The various restricted progenitor cells differ in their susceptibility to the cytolytic effects of anti-Thy-1 antiserum. Erythroid progenitors appear to lose the antigen more rapidly than any of the others tested, while macrophage precursors retain the antigen until relatively late in their developmental history. These differences in Thy-1 expression permit discrimination among the various progenitors.

Animals

Gene transfer in lymphoid cells: expression of the Thy-1.2 antigen by Thy-1.1 BW5147 lymphoma cells transfected with unfractionated cellular DNA.

We have transferred the gene coding for the Thy-1.2 alloantigen into a Thy-1.1-bearing T-cell lymphoma. BALB/c thymocyte DNA, precipitated with calcium phosphate, was used to effect the transfer. We report the stable transformation of lymphoid cells by total cellular DNA. To our knowledge, this has not been previously reported. Transient expression of the transfected gene could be detected by flow cytofluorometry, and 5% (range, 1.5%-11%) of the recipient cells had Thy-1.2 antigen detectable on their surface 48 hr after transfer. "Stable" transformants were isolated by repeatedly selecting for cells expressing the Thy-1.2 antigen, by use of fluorescence-activated cell sorting or "panning." No metabolic selection was required. The transferred gene, detected by Southern blotting, encoded a product that is indistinguishable from the normal antigen by immunoprecipitation and NaDod-SO4/PAGE.

Animals

A monoclonal antibody (AE3.d3) with mitogenic properties for murine B cells.

A monoclonal antibody, AE3.d3, derived from the fusion of rat splenocytes immunized against mouse brain with the myeloma SP2, has been produced, which has the property of inducing the proliferation of mouse lymphocytes. The mitogenic effect is highest in spleen and lymph node cells, where up to a 10-fold stimulation of 3H-TdR incorporation is observed. B lymphocytes are the most susceptible to this proliferative stimulus, and they are induced to differentiate into plaque-forming cells. T lymphocytes and "null" cells (defined by the absence of Thy-1 or Ig on their surface) do proliferate, although to a smaller extent. The T cell subpopulation, isolated from either spleen or thymus, requires additional "helper factors" in order to proliferate. The mitogenic response is not genetically restricted by H-2 type, and strains such as C3H/HeJ and CBA/N, in which B cell function is defective, as well as T cell-deficient strains such as BALB/c nude mice, are capable of responding to the stimulus of AE3.d3. Using immunofluorescence, we also examined the distribution of AE3.d3-positive cells in various lymphoid organs. The highest percentage of stained cells is found in the spleen (approximately 28%) and lymph node (18%), whereas only 14% of the bone marrow and 5% of the cells of the thymus are brightly stained with AE3.d3.

Animals

Cell separation using positive immunoselective techniques.

Positive immunoselection is the direct selection and recovery of cells which express a given specificity from among a heterogeneous group of contaminating cells. A variety of methods are available to effect such separations. The principles of affinity chromatography, using solid-phase matrices or cellular immunoadsorbents, are extensively used. Liquid-phase positive immunoselection can also be performed using either a fluorescence-activated cell sorter or by using 'cellular engineering' to protect a cell from an otherwise noxious environment. The enzyme catalase coupled to specific antibody has been used for this purpose and renders cells resistant to hydrogen peroxide. The various positive immunoselection techniques available are reviewed and evaluated in the following report.

Animals

MG-1: a specificity identifying members of the macrophage and granulocyte lineages of mice.

An antigen (MG-1) which behaves as a lineage marker for immature granulocytes and cells of the monocytic series in mice is described. It is identified by rabbit anti-mouse brain antiserum, which has been exhaustively absorbed with thymocytes, red blood cells, and a Thy-1 negative variant of a T-cell lymphoma. MG-1 is present on immature granulocytes, declines in its surface expression as the cells differentiate and is absent from the most mature cells (segmented) of the series. Early monocytes are strongly positive for MG-1 and, with maturity, the amount of cell surface antigen increases. Adherent, phagocytic macrophages are brilliantly positive when stained with anti-MG-1 antiserum in an immunofluorescence assay. The antigen is present on most of the adherent cells of the lung, spleen and peritoneum. Many multipotential stem cells also express low levels of this antigen as do some bone marrow B cells.

Animals

Thy-1 determinants are present on many murine hematopoietic cells other than T cells.

The development of a highly amplified immunofluorescence assay and the availability of monoclonal anti-Thy-1 antibodies have provided the methodology to reexamine the presence of Thy-1 antigen on murine lymphohematopoietic cells. The representation of this antigen is not, as previously believed, restricted to the T cell compartment of these cells. It is present on a significant number of mouse bone marrow cells (25-30%), including, as in the rat, multipotential stem cells, prothymocytes and some B cell precursors. Eosinophils and some immature myeloid cells are also antigen-positive.

Animals

Serologic identification of early members of the T cell lineage.

The SC-1 antigen, identified by thymus-absorbed rabbit anti-mouse brain antiserum, is present on multipotential stem cells. Its presence on cells of the T lineage has been examined by immunofluorescence, and we have demonstrated that it is also a marker for thymic development. Although it is present on the majority of fetal and neonatal thymocytes, its expression declines rapidly and, as early as 1 mo after birth, adult levels are reached. In normal animals, these do not change during adult life, even in mice destined to develop a T cell leukemia. SC-1 does reappear transiently on cells in the regenerating thymus of sublethally irradiated mice. Although the antigen is not associated with preleukemic changes in the thymus, it is expressed on some cells of all spontaneous T lymphomas, and it is uniformly present on tissue culture lines of T cell lymphomas.

Animals

Demonstration of a hematopoietic stem cell antigen (SC-1) on a murine lymphoma and isolation of variants lacking the antigen.

Murine multipotential hematopoietic stem cells (CFU-s) bear an antigen (SC-1) which is recognized by heterologous antisera to mouse brain. We have found that cloned Thy-1 negative variants of the T-cell lymphoma RL male 1 are sensitive to complement-mediated cytolysis by anti-brain serum and can absorb the anti-stem cell activity from the antiserum. We have isolated several subclones derived from a primary Thy-1 negative variant which are not susceptible to anti-brain serum. The surface of the resistant lines has little or no antigen capable of binding anti-mouse brain antibodies as measured by either immunofluorescence or a radioimmunoassay. These lines are also unable to absorb the antibodies responsible for the cytotoxic effect of rabbit anti-mouse brain serum against CFU-s. We conclude that the predominant antigen, serologically detectable on Thy-1 negative variants of RL male 1, is SC-1.

Animals